Innovent Biologics (1801N) Income Statement
1 Followers
Innovent Biologics Income Statement
Last quarter (Q2 2026), Innovent Biologics's total revenue was ¥8.50B, an increase of 115.04% from the same quarter last year. In Q2, Innovent Biologics's net income was ¥1.24B. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ¥ 13.04B | ¥ 9.42B | ¥ 6.21B | ¥ 4.56B | ¥ 4.27B | |
| ¥ 10.00B | ¥ 7.91B | ¥ 4.40B | ¥ 3.63B | ¥ 3.70B | |
| ¥ 9.26B | ¥ 7.65B | ¥ 6.08B | ¥ 6.21B | ¥ 5.75B | |
| Depreciation and Amortization | ¥ 601.32M | ¥ 419.77M | ¥ 385.10M | ¥ 319.42M | ¥ 204.75M |
| ¥ 1.33B | ¥ -336.10M | ¥ -660.68M | ¥ -1.75B | ¥ -2.37B | |
| ¥ 733.62M | ¥ -755.87M | ¥ -1.68B | ¥ -3.12B | ¥ -2.70B | |
| ¥ 105.30M | ¥ -336.74M | ¥ 534.89M | ¥ 952.38M | ¥ 61.63M | |
| ¥ 838.92M | ¥ -78.62M | ¥ -1.14B | ¥ -2.17B | ¥ -2.64B | |
| ¥ 813.57M | ¥ -94.63M | ¥ -1.03B | ¥ -2.18B | ¥ -2.73B | |
| Per Share Metrics | |||||
| Basic EPS | ¥ 0.48 | ¥ -0.06 | ¥ -0.66 | ¥ -1.46 | ¥ -1.88 |
| Diluted EPS | ¥ 0.47 | ¥ -0.06 | ¥ -0.66 | ¥ -1.46 | ¥ -1.88 |
| Weighted Average Shares Outstanding | 1.73B | 1.63B | 1.56B | 1.49B | 1.45B |
| Weighted Average Shares Outstanding (Diluted) | 1.74B | 1.63B | 1.56B | 1.49B | 1.46B |
Currency in CNY
